Nodes Logo
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Bioeclipse Therapeutics

Next-Generation Immunotherapies California, USA

| Overview |

Bioeclipse Therapeutics is developing novel, more effective immunotherapies against solid tumors by utilizing immune cells loaded with cancer-cell specific oncolytic viruses.




Series B


Capital Raise

Transaction Value



Next generation immunotherapies for solid tumors


  • Founded and renamed in 2017


Life Span Investments

Foothill Ventures

Delta Partners

Revelis Capital


Pamela Contag, PhD


9M deaths caused by drug resistance

An estimated 9 million people per year die of cancer due to drug resistance acquired by tumors against the original drug targets.


Cancer-targeting immune cells loaded with oncolytic viruses

Bioeclipse is developing next generation immunotherapies which utilizes cancer-targeting immune cells loaded with oncolytic viruses, generating a multi-pronged attack on hard-to-treat tumors.


USD 53B market

In the initial basket trial, Bioeclipse Therapeutics is targeting a range of solid tumors with a combined global market size greater than $53 billion.

"CRX100 addresses a significant unmet medical need in fatal conditions for which there are limited treatment options. CRX100, which migrates to the tumor site, targets tumor cells and delivers the cancer-destroying virus, has the potential to significantly help those with chemotherapy-resistant or refractory solid tumors"

Oliver Dorigo M.D., PhD (Director of the Gynecologic Cancer Service at Stanford University)

Get in touch

Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.